Advertisement

Autoimmune Bullous Dermatoses

  • Hiram de Almeida LarangeiraJr.
Chapter

Abstract

Autoimmune bullous dermatoses are acquired diseases associated with pathogenic autoantibodies against structural proteins that maintain cell–cell and cell–matrix adhesions in the skin and mucous membranes. They are classified as acantholytic (or intraepidermal) bullous dermatoses or non-acantholytic (or subepidermal) bullous dermatoses. Etiopathogenic, clinical, and therapeutic aspects are discussed in this chapter.

Keywords

Desmosome Hemidesmosome Acantholysis Immunofluorescence Immunosuppression 

Notes

Glossary

Acantholysis

Loss of epithelial intercellular contact, showing isolated round keratinocytes.

Bullous pemphigoid

Blistering dermatoses without acantholysis, caused by hemidesmosomal lesions.

Desmosome

Cell structure that adheres epithelial cells to each other, composed of two plaques, one in each cell, connected by transmembranous proteins.

Direct immunofluorescence

Laboratory investigation to detect antibodies in tissues.

Hemidesmosome

Cell structure that adheres the basal keratinocyte to the basement membrane, composed of one plaque, also connected by transmembranous proteins.

Pemphigus group

Blistering dermatoses with acantholysis caused by desmosomal lesions.

References

  1. 1.
    Zhu X, Pan J, Yu Z, Wang Y, Cai L, Zheng S. Epidemiology of pemphigus vulgarisin the Northeast China: a 10-year retrospective study. J Dermatol. 2014;41(1):70–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Herrero-González JE, Iranzo P, Benítez D, Lozano F, Herrero C, Mascaró JM Jr. Correlation of immunological profile with phenotype and disease outcome in pemphigus. Acta Derm Venereol. 2010;90(4):401–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int. 2011;108(23):399–405.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Qian Y, Prisayanh P, Andraca E, Qaqish BF, Aoki V, Hans-Filhio G, et al. IgE, IgM, and IgG4 anti-desmoglein 1 autoantibody profile in endemic pemphigus foliaceus (fogo selvagem). J Invest Dermatol. 2011 Apr;131(4):985–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Zhao CY, Murrell DF. Advances in understanding and managing bullous pemphigoid. F1000Res. 2015;4.Google Scholar
  6. 6.
    Kotze LM. Dermatitis herpetiformis, the celiac disease of the skin! Arq Gastroenterol. 2013;50(3):231–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Mendes FB, Hissa-Elian A, Abreu MA, Gonçalves VS. Review: dermatitis herpetiformis. An Bras Dermatol. 2013;88(4):594–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cunha PR, Barraviera SR. Autoimmune bullous dermatoses. An Bras Dermatol. 2009;84(2):111–24.CrossRefPubMedGoogle Scholar
  9. 9.
    James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29(3):405–12.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D. Management of pemphigus vulgaris: challenges and solutions. Clin Cosmet Invest Dermatol. 2015 Oct 21;8:521–7.CrossRefGoogle Scholar
  11. 11.
    Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013 Oct;169(4):916–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Clarindo MV, Possebon AT, Soligo EM, Uyeda H, Ruaro RT, Empinotti JC. Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment. An Bras Dermatol. 2014;89(6):865–77.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  1. 1.Federal and Catholic University of PelotasPelotasBrazil

Personalised recommendations